RPL22
Large ribosomal subunit protein eL22
Also known as: EAP, L22, RL22_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P35268
- Gene
- RPL22
- Ensembl
- ENSG00000116251
- Chromosome
- 1
- Canonical length
- 128 aa
- Protein class
- Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins
- Subcellular location
- Nucleoplasm,Nucleoli
OverviewNCBI Gene
Ribosomes, the organelles that catalyze protein synthesis, consist of a small 40S subunit and a large 60S subunit. Together these subunits are composed of 4 RNA species and approximately 80 structurally distinct proteins. This gene encodes a cytoplasmic ribosomal protein that is a component of the 60S subunit. The protein belongs to the L22E family of ribosomal proteins. Its initiating methionine residue is post-translationally removed. The protein can bind specifically to Epstein-Barr virus-encoded RNAs (EBERs) 1 and 2. The mouse protein has been shown to be capable of binding to heparin. Transcript variants utilizing alternative polyA signals exist. As is typical for genes encoding ribosomal proteins, there are multiple processed pseudogenes of this gene dispersed through the genome. It was previously thought that this gene mapped to 3q26 and that it was fused to the acute myeloid leukemia 1 (AML1) gene located at 21q22 in some therapy-related myelodysplastic syndrome patients with 3;21 translocations; however, these fusions actually involve a ribosomal protein L22 pseudogene located at 3q26, and this gene actually maps to 1p36.3-p36.2. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
128 residues, UniProt reviewed canonical sequence.
>P35268|RPL22
1 MAPVKKLVVK GGKKKKQVLK FTLDCTHPVE DGIMDAANFE QFLQERIKVN GKAGNLGGGV
61 VTIERSKSKI TVTSEVPFSK RYLKYLTKKY LKKNNLRDWL RVVANSKESY ELRYFQINQD
121 EEEEEDEDLocalizationUniProt · AlphaFold · HPA
Whether an antibody against RPL22 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.41
- Highest tissue expression
- 1,003 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 1,003 nTPM
- ovary: 943 nTPM
- skeletal muscle: 855 nTPM
- pancreas: 651 nTPM
- skin: 624 nTPM
- lymph node: 617 nTPM
Single-cell type
- cardiomyocytes: 1,139 nCPM
- gastric chief cells: 988 nCPM
- parietal cells: 746 nCPM
- mucous neck cells: 627 nCPM
- fallopian secretory cells: 476 nCPM
- ovarian stromal cells: 476 nCPM
Immune cell
- naive CD4 T-cell: 681 nTPM
- total PBMC: 665 nTPM
- naive CD8 T-cell: 563 nTPM
- memory B-cell: 549 nTPM
- memory CD4 T-cell: 504 nTPM
- naive B-cell: 503 nTPM
Brain region
- white matter: 155 nTPM
- spinal cord: 140 nTPM
- hypothalamus: 134 nTPM
- basal ganglia: 131 nTPM
- medulla oblongata: 129 nTPM
- choroid plexus: 126 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.04
- gnomAD pLI
- 0.16
- gnomAD missense Z
- 1.67
- DepMap mean gene effect
- -0.71
- DepMap dependency class
- common
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- alpha-beta T cell differentiation
- cytoplasmic translation
- translation
- translation at presynapse
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of RPL22 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads RPL22 as an antibody target. Whether an autoantibody or antibody against RPL22 could matter depends on whether native RPL22 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
RPL22 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label RPL22 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...